Natera director Roy Baynes sells $5.44 million worth of stock via Investing.com
Roy Baynes, director at Natera, Inc. (NASDAQ:NTRA), has recently made several transactions involving the company’s common stock, according to a filing with the Securities and Exchange Commission. On November 15, Baynes sold a large amount of shares, a total of $5.44 million. The shares were traded at prices ranging from $144.258 to $149.9788 per share.
In addition to sales, Baynes acquired shares through the exercise of stock options. The transaction involved the acquisition of 22,000 shares at $22.83 per share and 15,230 shares at $24.42 per share, for a total of approximately $874,176.
The sale was made under the 10b5-1 pre-arranged trading plan, which allows insiders of publicly traded companies to set up a trading plan to sell the stocks they own. Following this transaction, Baynes owns 15,807 shares of Natera.
In other recent news, Company Natera Inc (NASDAQ:). Reported record Q3 revenue of $439.8 million, a 64% year-over-year increase. The company’s net income reached a record 62%, and generated cash flow of $34.5 million. Based on these strong financial results, Natera revised its full-year revenue guidance to between $1.61 billion and $1.64 billion. The company experienced a significant increase in oncology test volumes, with 137,000 tests performed, a 54% increase over last year.
In response to these impressive results, TD Cowen, Baird, and Jefferies expressed confidence in Natera by maintaining positive ratings and raising their price targets. TD Cowen raised its price target to $175, Baird to $160, and Jeffery to $182. These companies highlighted Natera’s operational success and potential for continued growth.
In addition to its financial achievements, Natera reported promising results predicting overall survival and chemotherapy benefits in colorectal cancer with its Signatera trial. The company also noted strong performance in women’s health, including the launch of the Fetal RhD test. Despite facing challenges with private payers and potential disruptions related to the holidays, Natera sees significant growth opportunities with more than 100 trials underway.
InvestingPro Insights
Roy Baynes’ recent insider trades at Natera, Inc. (NASDAQ:NTRA) comes at a time when the company’s stock has shown impressive performance. According to InvestingPro data, Natera has delivered a significant return of 176.58% over the past year, with a solid return of 34.62% over the past six months. This coincided with a period of sales of Baynes’ stock, which occurred at prices between $144.258 and $149.9788 per share.
InvestingPro Tips highlights that Natera’s stock price movements are volatile, which may explain the director’s decision to sell under the 10b5-1 pre-arranged trading plan. Despite these fluctuations, the company has seen significant market growth, currently standing at $19.35 billion.
It is worth noting that while Natera has experienced impressive revenue growth of 54.94% over the past twelve months, with Q3 2024 showing a strong quarterly increase of 63.9%, the company has yet to turn a profit. InvestingPro’s tip indicates that analysts don’t expect the company to turn a profit this year, which could be a factor for investors to think about along with the stock’s strong performance.
For those who want a deeper understanding of Natera’s financial health and market conditions, InvestingPro offers 14 additional tips, providing a comprehensive analysis of informed investment decisions.
This article was created with the support of AI and reviewed by an editor. For more information see our T&C.
